Vice President, Emerging Therapies

Alicia Silver, MPP

Alicia has over a decade of experience in health policy, reimbursement and market access focused on bone marrow transplant and cell and gene therapy across many indications. Before joining ADVI, Alicia led many Medicare coverage and reimbursement initiatives as well as commercial readiness efforts with hospitals and all payers. Earlier in her career, Alicia led a Health Economics & Market Access team for a cell therapy device manufacturer, looking at automation efficiencies and transfusion medicine. Alicia also led a Health Policy and Reimbursement team at the National Marrow Donor Program/Be The Match. Alicia is passionate about improving access to life-changing therapies by weaving together complex health policy, reimbursement strategies and the patient story.

Alicia holds a Masters of Public Policy degree from the University of Minnesota Humphrey School of Public Affairs, a Certificate in Business Strategy from Cornell University and a Bachelor of Arts degree in Political Science from the University of Wisconsin-Madison.

CEO insights

Real analysis from people who’ve been there

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Devices

ADVI Instant: CMS Releases the Final Notice for TCET and 3 NCD Documents

On August 7, 2024, CMS released the final notice for the Transitional Coverage for Emerging Technologies (TCET) pathway (link) and …

Alicia Silver, MPP
August 16, 2024

ADVI Instant

Pharmaceuticals and Biotech

ADVI Instant: OSTP Releases Report on US Biotech and Biomanufacturing Goals

On March 24, 2023, in response to Executive Order 14081, the White House Office of Science and Technology Policy released a report outlining the administration’s goals for the U.S. bioeconomy. In the area of health, the White House hopes to “increase the manufacturing scale of cell-based therapies to expand access, decrease health inequities, and decrease the manufacturing cost of cell-based therapies 10-fold.” Read the ADVI Angle of the report highlights in our ADVI Instant.

Alicia Silver, MPP
March 24, 2023

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.